OXiGENE, Inc. (NASDAQ: OXGN)

OXiGENE, Inc. (NASDAQ: OXGN), a biopharmaceutical company, is focused on finding and developing new and improved therapeutics that attend to the substantial, but unmet needs of patients diagnosed with cancer and eye disease. The company’s primary focus is on the development and commercialization of first-in-class and best-in-class vascular disrupting agents (VDAs) designed to treat cancer and eye disease. To date, OXiGENE’s VDA product candidates have shown considerable potential in human clinical studies. For further information, visit the Company’s web site at www.oxigene.com.